U.S. top court rejects Amgen over cholesterol medication patent fight

Australia News News

U.S. top court rejects Amgen over cholesterol medication patent fight
Australia Latest News,Australia Headlines
  • 📰 Reuters
  • ⏱ Reading Time:
  • 1 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 4%
  • Publisher: 97%

The U.S. Supreme Court on Monday declined to take up Amgen Inc's bid to rei...

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Reuters /  🏆 2. in US

Australia Latest News, Australia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Amgen CEO on cholesterol drug price cut: 'Too many patients' were struggling to payAmgen CEO on cholesterol drug price cut: 'Too many patients' were struggling to payJim Cramer sits down with Amgen Chairman and CEO Bob Bradway to hear about the company's recent price cut for one of its key drugs.
Read more »

Stocks making the biggest moves after hours: Apple, Amgen, AMD and moreStocks making the biggest moves after hours: Apple, Amgen, AMD and moreSee which stocks are posting big moves after the bell on January 29.
Read more »

From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019Billion-dollar deals from drug giants Eli Lilly & Co. and Bristol-Myers Squibb could set the tone for a year full of healthcare acquisitions.
Read more »

House Democrats launch drug-pricing probe into a dozen major health-care companiesHouse Democrats launch drug-pricing probe into a dozen major health-care companiesAbbVie, Amgen, AstraZeneca, Celgene, Eli Lilly, Johnson & Johnson, Mallinckrodt, Novartis, Novo Nordisk, Pfizer, Sanofi and Teva Pharmaceuticals received letters seeking detailed information and documents about the companies' pricing practices.
Read more »

U.S. lawmaker launches investigation into pharma drug pricingU.S. lawmaker launches investigation into pharma drug pricingRepresentative Elijah Cummings, who chairs the House Oversight Committee, sent letters to 12 drugmakers seeking information on price increases, investment in research and development, and corporate strategies to preserve market share and pricing power, his office said in a statement. Novo Nordisk, Amgen
Read more »

Biotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reportsBiotech is breaking out. Here's what one analyst says to watch ahead of 3 key earnings reportsBiotech stocks are on a roll so far this year. With Amgen, Biogen, and Celgene all set to report earnings this week, here's what Baird biotech analyst Brian Skorney says investors should be watching.
Read more »



Render Time: 2025-03-06 19:12:29